Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Limited, an Australian company specializing in FAK inhibitors for cancer and fibrosis treatment, has announced a significant change in director Dr. Robert Peach’s interests, with an acquisition of 1,900,005 shares through an entitlement offer at $0.055 per share. This development could indicate a bolstering of internal confidence in the company’s prospects.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
